Cancer is one of the most devastating and deadly diseases of all time. It can strike at any time and for anyone. There are many different forms of cancer as it can affect a person’s lungs, skin, brain or bones. Cancer treatments have been going on for decades and decades. It feels like a never ending battle that can’t be won, but over the past decade, there have been some innovative new treatments introduced to the market. One of the drugs is known as ADCETRIS, and it delivers a killing blow to cancer cells. It does so by injecting powerful medications into the cancerous cell itself.
One of the leading biotech companies in the world that specializes in these treatments is located in Bothell, Washington. Seattle Genetics stands over everyone and everything else when comes to fighting this deadly disease. The company has been around since 1998, and it has grown into a powerhouse of an institution. Its basically the “holy grail” of cancer research. Though it’s not flawless, the company is saving more lives now than the entire industry did years ago. Dr. Clay Siegall is the president and the CEO of Seattle Genetics. This guy has many titles, which includes:
He’s written up to 70 different publications, and currently holds up to 15 patents. Can you name another individual with accolades like this? Siegall has been in the game for many years by working with many prominent names such as Bristol Myers Squibb and the National Cancer Institute. The guy has a B.S. in Zoology from the University of Maryland as well as a Ph.D in Genetics from George Washington University.
Siegall shined the light on cancer itself as he produces plenty of consistent content on his blog. He recently informed the public on the future plans of Seattle Genetics as well as some of the up and coming medications. Siegall spoke on trial readouts and the medication SGN-LIV1A, which is for breast cancer. The future of cancer research is in great hands and Dr. Clay Seigall is in control of it all.